Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson’s Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F24%3A10158847" target="_blank" >RIV/00098892:_____/24:10158847 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/24:00081261 RIV/00216224:14110/24:00138483 RIV/00216208:11110/24:10488975 RIV/61989592:15110/24:73626859 RIV/00064165:_____/24:10488975

Výsledek na webu

<a href="https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/100132" target="_blank" >https://journals.viamedica.pl/neurologia_neurochirurgia_polska/article/view/100132</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5603/pjnns.100132" target="_blank" >10.5603/pjnns.100132</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson’s Disease

Popis výsledku v původním jazyce

Aim of study: To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. Clinical rationale for study: Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson’s Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from subclinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation. The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. Material and methods: A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. Results: Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation. The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695–3,184) and 1,898 (1,484–2,167) mg, respectively. The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. Conclusions and clinical implications: The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.

Název v anglickém jazyce

Acute polyneuropathy: a serious complication of levodopa/ /carbidopa intestinal gel treatment for Parkinson’s Disease

Popis výsledku anglicky

Aim of study: To determine whether a high dose of levodopa-carbidopa intestinal gel (LCIG), expressed as levodopa equivalent daily dose (LE daily dose), is a risk factor for acute polyneuropathy in patients treated with LCIG. Clinical rationale for study: Treatment with LCIG is an effective device-assisted therapy in the advanced stages of Parkinson’s Disease (PD). Polyneuropathy is a well-known complication of PD treatment. Patients treated with oral levodopa usually suffer from subclinical or mild chronic sensory polyneuropathy. However, severe acute polyneuropathy occurs in patients treated with LCIG, which is causally related to the treatment and leads to its immediate discontinuation. The etiology is not yet clear, but some patients with acute polyneuropathy have been given high doses of LCIG. Material and methods: A retrospective multicentre study of patients treated with LCIG was performed. Patients with acute polyneuropathy were subjected to a detailed analysis including statistical processing. Results: Of 183 patients treated with LCIG in seven centres, six patients (five females, median age 63 years) developed acute polyneuropathy with LCIG discontinuation. The median (interquartile range) initial and final LE daily dose in patients with and without acute polyneuropathy was 3,015 (2,695–3,184) and 1,898 (1,484–2,167) mg, respectively. The final LE daily dose of 2,605 mg cut-off had 83% sensitivity and 93% specificity for the prediction of acute polyneuropathy. Conclusions and clinical implications: The risk of acute polyneuropathy in LCIG-treated patients was associated with a daily LE dose of greater than 2,605 mg or with more than a 62% increase in the daily LE dose during LCIG treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

<a href="/cs/project/LX22NPO5107" target="_blank" >LX22NPO5107: Národní ústav pro neurologický výzkum</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neurologia i Neurochirurgia Polska

ISSN

0028-3843

e-ISSN

1897-4260

Svazek periodika

58

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

7

Strana od-do

586-592

Kód UT WoS článku

001360325600001

EID výsledku v databázi Scopus

2-s2.0-85213726825